Insights on the SARM1 Inhibitors Global Market to 2040 - Players Profiled Include Disarm Therapeutics, Nura Bio and Washington University
Saturday, February 4, 2023
DUBLIN, Dec. 23, 2022 /PRNewswire/ -- The "SARM1 Inhibitors Market by Target Indications, Type of Molecules, Drug Developers, Drug Candidates and Key Geographies: Industry Trends and Global Forecasts, 2022-2040" report has been added to ResearchAndMarkets.com's offering.
https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
This report features an extensive study of the current landscape, offering an informed opinion on the likely adoption of SARM1 inhibitors therapeutics in the healthcare domain, till 2040. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this market space.
Neurological disorders are considered the second leading cause of death and the primary cause of long-term disability, worldwide. Across the globe, over 6.5 million neurological disorder related deaths are reported annually. Further, according to a report published by the United Nations (UN), close to 1 billion people, globally, suffer from various types of neurological disorders.
The growing number of patients suffering from neurodegenerative disorders has imposed a huge burden, in terms of finances as well as resources, on the overall healthcare system. In fact, the annual expenditure associated with neurological disorder care in 2020 was more than USD 655 billion, in the US alone.
Given the fact that majority of the current treatment options have proven to be inadequate, especially for axonal degeneration associated neurological disorders, there is a high demand for highly effective therapeutics targeting neurological disorders. Interestingly, Sterile Alpha and toll / Interleukin-1 Receptor Motif-Containing 1 (SARM1), an NADase enzyme, has been found to play a critical role in inducing axonal degeneration, which is a central pathological feature in various neurodegenerative disorders.
Presently, several industry and non-industry stakeholders are evaluating SARM1 inhibitors as potential therapeutic agents for the treatment of neurological disorders, such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and multiple sclerosis across various preclinical studies and early stages of clinical development, worldwide. Given the encouraging research outcomes, the players in this domain have received more than USD 10 million in grants, since 2014, from the various private and public organizations.
Additionally, several patents related to SARM1 inhibitors have been recently filed / granted, demonstrating the continued innovation in this domain. Driven by the ongoing pace of innovation in this field, increasing R&D activity and promising pre-clinical data, several promising leads are anticipated to be commercially launched over the coming decade and SARM1 inhibitors market is anticipated to witness substantial growth in the mid to long-term.
Frequently Asked Questions
-- Who are the leading players engaged in the development of SARM1
inhibitors therapeutics?
-- What is the evolving trend of publications focused on SARM1 inhibitors
therapeutics?
-- How is the intellectual property landscape in this field likely to
evolve in the foreseen future?
-- What are the recent developments and strategic initiatives undertaken by
players engaged in this market space related to research and development
of SARM1 inhibitors therapeutics?
-- What are the key value drivers that are likely to influence the
evolution of this upcoming market?
-- How is the current and future market opportunity likely to be
distributed across key market segments?
Key Topics Covered:
1. EXECUTIVE SUMMARY
2. INTRODUCTION
2.1. Overview of SARM1
2.2. Role of SARM1 in Neurodegenerative Disorders
2.2.1. Mechanism of Action of SARM1
2.3. Mechanism of SARM1 Pathway Inhibition
2.4. Future Perspectives of SARM1 inhibitors Therapeutics
3. MARKET LANDSCAPE
3.1. SARM1 Inhibitors: Pipeline Review
3.1.1 Analysis by Phase of Development
3.1.2. Analysis by Type of Molecule
3.1.3. Analysis by Phase of Development and Type of Molecule
3.1.4. Analysis by Target Indication
3.1.5. Analysis by Type of Developers
3.1.6. Analysis by Phase of Development and Target Indication
3.2. SARM1 Inhibitors: Developer Landscape
3.2.1. Analysis by Year of Establishment
3.2.2. Analysis by Company Size
3.2.3. Leading Developers: Analysis by Number of Candidates
3.2.4. Regional Landscape by Type of Player
4. COMPANY COMPETITIVENESS ANALYSIS
4.1. Assumptions and Key Parameters
4.2. Methodology
4.3. Company Competitive Analysis: Industry Players
4.4. Company Competitive Analysis: Non-Industry Players
5. COMPANY PROFILES
5.1. Disarm Therapeutics
5.1.1. Company Overview
5.1.2. Product Portfolio
5.1.3. Recent Patent Portfolio
5.1.4. Recent Developments and Future Outlook
5.2. Nura Bio
5.2.1. Company Overview
5.2.2. Product Portfolio
5.2.3. Recent Patent Portfolio
5.2.4. Recent Developments and Future Outlook
5.3. Washington University
5.3.1. Company Overview
5.3.2. Product Portfolio
5.3.3. Recent Patent Portfolio
5.3.4. Recent Developments and Future Outlook
6. PUBLICATION ANALYSIS
6.1. Methodology and Parameters
6.2. SARM1 inhibitors Therapeutics: Publication Analysis
6.2.1. Analysis by Year of Publication
6.2.2. Analysis by Type of Publication
6.2.3. Most Popular Journals: Analysis by Number of Publications
6.2.4. Most Popular Journals: Analysis by Journal Impact Factor
6.2.5. Popular Keywords: Analysis by Key Focus Areas
6.2.6. Most Active Publishers: Analysis by Number of Publications
6.2.7. Most Popular Affiliations: Analysis by Number of Publications
6.2.8. Analysis by Geography
7. GRANT ANALYSIS
7.1. Scope and Methodology
7.2. Key Parameters
7.3. SARM1 inhibitors Therapeutics: Grant Analysis
7.3.1. Analysis by Year of Grant Awarded
7.3.2. Analysis by Support Period
7.3.3. Analysis by Amount Awarded
7.3.4. Analysis by Leading Funding Institute Centre
7.3.5. Analysis by Type of Grant
7.3.6. Analysis by Activity Code
7.3.7. Analysis by Study Section Involved
7.3.8. Analysis by Purpose of Grant
7.3.9. Prominent Program Officers: Analysis by Number of Grants
7.3.10. Popular Recipient Organizations: Analysis by Number of Grants and Amount Awarded
7.3.11. Most Popular Departments: Analysis by Number of Grants
7.3.12. Analysis by Location of Recipient
8. PATENT ANALYSIS
8.1. Scope and Methodology
8.2. Key Parameters
8.3. SARM1 inhibitors Therapeutics: Patent Analysis
8.3.1. Analysis by Type of Patent
8.3.2. Analysis by Publication Year
8.3.3. Analysis by Application Year
8.3.4. Analysis by Geography
8.3.5. Analysis by CPC Symbols
8.3.6. Analysis by Type of Applicant
8.3.7. Analysis by Focus Area
8.3.8. Analysis by Patent Age
8.3.9. Leading Industry Players: Analysis by Number of Patents
8.3.10. Leading Non-Industry Players: Analysis by Number of Patents
8.3.11. Leading Individual Assignees: Analysis by Number of Patents
8.4. SARM1 inhibitors Therapeutics: Patent Benchmarking Analysis
8.4.1. Analysis by Patent Characteristics
8.5. SARM1 inhibitors Therapeutics: Patent Valuation
9. RECENT DEVELOPMENTS
9.1. List of Recent Developments
10. MARKET FORECAST AND OPPORTUNITY ANALYSIS
10.1. Key Parameters and Assumptions
10.2. Methodology
10.3. SARM1 inhibitors Therapeutics: List of Forecasted Drugs
10.4 Global SARM1 inhibitors Therapeutics Market, 2033, 2037 and 2040
10.4.1. SARM1 inhibitors Therapeutics Market: Distribution by Target Indication, 2037 and 2040
10.4.2. SARM1 inhibitors Therapeutics Market: Distribution by Type of Molecule, 2033, 2037 and 2040
10.4.3. SARM1 inhibitors Therapeutics Market: Distribution by Drug Developer, 2037 and 2040
10.4.4. SARM1 inhibitors Therapeutics Market: Distribution by Drug Candidate, 2037 and 2040
10.4.5. SARM1 inhibitors Therapeutics Market: Distribution by Geography, 2037 and 2040
10.5. SARM1 inhibitors Therapeutics Market: Forecast of Individual Product Sales
10.5.1 DSRM-3716 (Disarm Therapeutics): Sales Forecast
10.5.2 Unnamed Molecule 1 (Disarm Therapeutics): Sales Forecast
10.5.3 Unnamed Molecule 2 (Disarm Therapeutics): Sales Forecast
10.5.4 Unnamed Molecule 3 (Disarm Therapeutics): Sales Forecast
10.5.5 Unnamed Molecule (Nura Bio): Sales Forecast
10.5.6 Unnamed Molecule (King's College London): Sales Forecast
11. APPENDIX 1: LIST OF FIGURES
12. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
For more information about this report visit https://www.researchandmarkets.com/r/3rw5ax
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/insights-on-the-sarm1-inhibitors-global-market-to-2040---players-profiled-include-disarm-therapeutics-nura-bio-and-washington-university-301709581.html
SOURCE Research and Markets
|
|
|
|
|
 |
Weekly Recap: 11 Tech Press Releases You Need to See | Jan 22, 2026
|
|
Sup AI Sets New Benchmark Record with 52.15% on Humanity's Last Exam | Jan 22, 2026
|
|
DEADLINE ANNOUNCED FOR 2026 NEW TOP-LEVEL DOMAIN APPLICATIONS | Jan 22, 2026
|
|
Skunk Works® and XTEND Expand Joint All Domain Command and Control for Advanced Mission Execution | Jan 22, 2026
|
|
Trigent Partners with WeWork India to Expand its GCC Footprint | Jan 22, 2026
|
|
Exia Labs Brings Keystone to the U.S. Navy via DIU's Blue Object Management Challenge | Jan 22, 2026
|
|
Altair HyperWorks 2026 Delivers Design and Simulation at Scale with AI | Jan 22, 2026
|
|
Glasswall Brings Defense-Level File Sanitization to Every Government Agency and Business Using Microsoft 365 | Jan 22, 2026
|
|
Genpact Named a Leader in ISG Provider Lens(TM) 2025 for Insurance GCCs and Agentic AI Services | Jan 22, 2026
|
|
The Roadmap to Securing Your Own Digital Domain is Now Available | Jan 22, 2026
|
|
|
